Medicus Pharma
Medicus Pharma is a Toronto-based, clinical-stage biotech developing a dissolvable microneedle 5-FU therapy (SkinJect) for basal cell carcinoma and a GnRH antagonist (Teverelix) for prostate cancer, endometriosis, and BPH, with no current product revenue.
- Company typePublic
- Founded2008
- HeadquartersToronto, Canada
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Medicus Pharma does
Medicus Pharma Ltd. (NASDAQ: MDCX) is a Toronto-based, Canadian-incorporated clinical-stage biotechnology company developing non-systemic therapies for dermatologic and endocrine indications. Its two lead assets are SkinJect, a dissolvable microneedle array (D-MNA) delivering 5-fluorouracil for the treatment of basal cell carcinoma, and Teverelix, a GnRH antagonist targeting advanced prostate cancer, endometriosis, and benign prostatic hyperplasia that was added via the September 2025 acquisition of Antev Ltd. The lead SkinJect program reported positive Phase 2 topline data in March 2026 with 73% clinical clearance in the 200µg cohort, while Teverelix received an FDA Study May Proceed letter in February 2026 to commence a Phase 2b trial in advanced prostate cancer, with Orphan Drug Designation and Rare Pediatric Disease Designation pending.
The company operates a pre-revenue, R&D-driven business model with no marketed products and no recurring customer revenue. Future monetization is expected to come from out-licensing or partnering SkinJect and Teverelix to larger pharmaceutical companies, supplemented by potential milestone and royalty streams. To date, operations have been financed almost entirely by equity, warrant, debenture, and structured-financing transactions — including a $4.93M raise in 2023, $7M in May 2025, an $8M debenture in September 2025, $5.1M and $15.3M ATM-related raises in December 2025, and a $22M structured facility in May 2026 — with FY2025 net losses of $35.4M and Q1 2026 net losses of $9.0M. Headcount sits in the 11–50 range, and the company has disclosed a going-concern doubt and Nasdaq minimum bid price non-compliance in April 2026. Strategic ancillary initiatives include a January 2026 Reliant AI partnership for clinical data analytics, a UK clinical footprint, and a UAE expansion tied to a national genome program, but these remain early-stage and do not yet contribute revenue.
Medicus Pharma firmographics
Firmographics- Name
- Medicus Pharma
- Legal name
- Medicus Pharma Ltd.
- Website
- https://medicuspharma.com
- Company type
- Public
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Medicus Pharma is a Toronto-based, clinical-stage biotech developing a dissolvable microneedle 5-FU therapy (SkinJect) for basal cell carcinoma and a GnRH antagonist (Teverelix) for prostate cancer, endometriosis, and BPH, with no current product revenue.
- Ownership category
- akta.pro rank
Where Medicus Pharma is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
Medicus Pharma business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Others
Revenue model
- Pre-revenue (clinical-stage): Medicus Pharma is a clinical-stage biotech with no approved products; reported FY2025 net loss of $35.4 million and Q1 2026 net loss of $9.0 million. Anticipated future revenue is expected to come from out-licensing of SkinJect and Teverelix assets to established pharmaceutical companies for late-stage development and commercialization.
- Capital markets financing (non-operating): Company funds operations through capital raises including an Equity Distribution Agreement / ATM program up to $50 million, $22 million structured financing facility, $8 million non-dilutive debenture, warrant inducements, and SEPA facilities. Operations are not yet revenue-generating.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels8 records
Medicus Pharma product offering
Product offeringCore offering
Medicus Pharma is a precision-guided, clinical-stage biotech company that acquires and accelerates the development of novel therapeutic assets through Phase 2 proof-of-concept, then pursues licensing or strategic partnerships with established pharmaceutical companies for late-stage development and commercialization. Its pipeline includes SkinJect (a Doxorubicin Microneedle Array patch for basal cell carcinoma and Gorlin Syndrome) and Teverelix (a long-acting GnRH antagonist for advanced prostate cancer, acute urinary retention, and endometriosis).
Product overview
Medicus Pharma operates a precision-guided biotech portfolio model: a single parent platform (Medicus Pharma Ltd., NASDAQ: MDCX) that acquires and accelerates clinical-stage therapeutic assets through Phase 2 proof-of-concept before seeking licensing or strategic partnerships for late-stage development and commercialization. The core portfolio currently consists of two therapeutic programs — SkinJect (D-MNA, a doxorubicin microneedle array patch for basal cell carcinoma and Gorlin Syndrome, advanced through subsidiary SkinJect Inc.) and Teverelix (a long-acting GnRH antagonist acquired via Antev Ltd. for advanced prostate cancer, acute urinary retention, and endometriosis). These clinical assets are wrapped by an emerging AI-enabled drug development capability, including an agentic AI-enabled clinical platform and a Reliant AI co-developed clinical data analytics platform for site selection, patient stratification, and enrollment forecasting, intended to compress timelines across the portfolio.
Differentiator
Problem solved
Functional benefit
Brands
- SkinJect: Portfolio company of Medicus Pharma developing a Doxorubicin Microneedle Array (D-MNA) for non-invasive treatment of basal cell carcinoma and Gorlin Syndrome.
- Antev Ltd
Products and services
- SkinJect (D-MNA: Doxorubicin Microneedle Array) Investigational, non-surgical drug-device combination delivering doxorubicin directly into tumors via a dissolvable microneedle array patch for the non-invasive treatment of nodular basal cell carcinoma, including patients with Gorlin Syndrome (NBCCS). Advanced through wholly-owned subsidiary SkinJect Inc.
- Teverelix Long-acting next-generation GnRH antagonist in development for advanced prostate cancer (including a cardiovascular high-risk population), acute urinary retention associated with benign prostatic hyperplasia, and endometriosis. Acquired via the September 2025 acquisition of UK-based Antev Limited.
- PRECISION-E2 (Teverelix Endometriosis Phase 2a) Phase 2a genomics-enabled clinical trial program evaluating Teverelix in women with symptomatic endometriosis across multiple UAE sites, integrating the Emirati Genome Program to explore how genetic variation influences response to hormonal therapy.
Quantifiable outcome
- Phase 2 SkinJect 200µg cohort: 73% clinical clearance and 40% histological clearance at Day 57 (90 patients)
- +4 more outcomes
Companies that use Medicus Pharma
Customer profileSegments5 records
Ideal customer profiles4 records
Medicus Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature4 records
Medicus Pharma partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- UAE Genome Program (Emirati Genome Program)coreCollaboration enabling the PRECISION-E2 Phase 2a genomics-enabled clinical trial evaluating Teverelix in women with symptomatic endometriosis in the UAE. The trial leverages the Emirati Genome Program to explore how genetic variation influences response to hormonal therapy, representing one of the first prospective studies integrating genomic profiling with hormonal modulation in endometriosis.
- House Energy & Commerce Committee (US Congress)coreCEO Dr. Raza Bokhari and leadership team met with senior members of the House Energy & Commerce Committee on Capitol Hill (including Chair Brett Guthrie) in collaboration with the Gorlin Syndrome Alliance to advocate for Orphan Drug Designation and Registrational IND approval for SkinJect in Gorlin Syndrome. Engagement targets key committee chairs and caucus co-chairs shaping US rare disease policy.
- New to The Streetcore12-part national media series highlighting SkinJect and Teverelix platforms, broadcast on Bloomberg Television across the US, MENA, and Latin America. Builds on an earlier six-part media series (Feb 2026) to raise Medicus' visibility among investors and healthcare communities.
- Omics LabsminorCollaboration to explore development of Teverelix for endometriosis in the United Arab Emirates. Positioned as part of the broader plan to advance Teverelix as potentially the first long-acting injectable GnRH antagonist for women's health indications.
- Brookline Capital MarketsminorHosted fireside chat featuring Medicus Pharma discussing positive Phase 2 SkinJect topline results (73% clinical clearance in 200-µg arm). Biotechnology equity research analyst engagement to communicate clinical and corporate developments to investors.
- Reliant AI Inc.coreNon-binding letter of intent to jointly develop an AI-powered clinical data analytics platform for clinical trial execution. Initial one-year, milestone-based engagement capped at $200,000 focuses on dynamic site selection, patient stratification, and enrollment forecasting for an upcoming Teverelix clinical study planned for 2026. Potential expansion to a larger late-stage study in 2028. Platform integrates Reliant's AI technology with Medicus' clinical, operational, and proprietary datasets.
- Helix NanotechnologiescoreNon-binding Memorandum of Understanding (MoU) with Helix Nanotechnologies referenced in connection with advancing Medicus' therapeutics and microneedle technology programs. Specific scope and financial terms not disclosed in available sources.
- Gorlin Syndrome AlliancecoreCollaboration to pursue a compassionate use / expanded access pathway for SKINJECT in patients with Gorlin Syndrome through the FDA's Expanded Access IND Program. Joint effort to collect real-world safety data to support future regulatory filings and expand clinical trials, while also collaborating on Capitol Hill advocacy for orphan drug designation.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Medicus Pharma competitors and assessment
Company assessmentDirect peers
- Sol-Gel Technologies: Clinical and commercial dermatology company developing topical therapies for skin conditions including basal cell carcinoma (with generic and branded assets). Highly comparable to Medicus given its focus on BCC treatment and recent clinical pipeline activity.
- Biofrontera Inc. Commercial-stage dermatology company marketing Ameluz and BF-RhodoLED for actinic keratosis and exploring basal cell carcinoma indications. Comparable to Medicus as a US-focused dermatology player targeting non-melanoma skin cancer with a procedural/drug-device approach.
- Myovant Sciences (Sumitomo Pharma / Pfizer): Developer of Orgovyx (relugolix), an FDA-approved oral GnRH antagonist for advanced prostate cancer. Direct competitor to Teverelix in the long-acting GnRH antagonist category for prostate cancer, with established commercial infrastructure.
- Tolmar Pharmaceuticals: Specialty pharmaceutical company with Eligard (leuprolide) and supplying a long-acting injectable GnRH agonist in prostate cancer. Comparable to Medicus in the hormonal prostate cancer therapy space where Teverelix is positioning itself.
Broad incumbents
- Sun Pharmaceutical Industries (Levulan/Kerastick): Large global pharmaceutical company with an approved photodynamic therapy (Levulan/kerastick) used in BCC treatment. Relevant comparable as an incumbent offering an established non-surgical BCC modality against which SkinJect would compete or pair.
- PellePharm (a LEO Pharma company): Developed patidegib (a hedgehog pathway inhibitor) for Gorlin Syndrome under LEO Pharma. Most direct prior competitor in Gorlin Syndrome BCC treatment, providing historical context for the regulatory and clinical bar Medicus must clear with SkinJect.
Emerging players
- Vaxxas: Clinical-stage company developing dissolvable microarray patch technology for vaccine and therapeutic delivery. Comparable to Medicus from a microneedle/drug-device delivery platform perspective (relevant to SkinJect D-MNA).
- Aclaris Therapeutics: Clinical-stage dermatology therapeutics company developing novel topical and immuno-modulatory therapies for skin diseases including rare dermatologic indications. Comparable to Medicus as a small-cap clinical-stage dermatology biotech pursuing niche indications.
- Krystal Biotech: Commercial-stage genetic medicines company that leveraged Orphan Drug and Rare Pediatric Disease Designations to commercialize Vyjuvek. Highly comparable as a small-cap biotech that successfully translated rare-disease designations into commercial value, illustrating the regulatory pathway Medicus is pursuing.
Others
- Reliant AI Inc. AI-driven clinical data analytics platform partner co-developing Medicus's site selection, patient stratification, and enrollment forecasting capability. Relevant as the technology partner enabling Medicus's 'agentic AI-enabled drug development' narrative.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights6 records
Customer concentration
Medicus Pharma social profiles
Digital presenceMedicus Pharma compliance and trust
Trust signalCompliance4 records
Medicus Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medicus Pharma leadership team
Management profileNumber of profiles
Profiles3 records
Medicus Pharma subsidiaries and ownership
Company hierarchySubsidiaries2 records
Medicus Pharma funding detail
Funding detailFunding overview
Funding rounds6 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medicus Pharma M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medicus Pharma
What does Medicus Pharma do?
Medicus Pharma is a precision-guided, clinical-stage biotech company that acquires and accelerates the development of novel therapeutic assets through Phase 2 proof-of-concept, then pursues licensing or strategic partnerships with established pharmaceutical companies for late-stage development and commercialization. Its pipeline includes SkinJect (a Doxorubicin Microneedle Array patch for basal cell carcinoma and Gorlin Syndrome) and Teverelix (a long-acting GnRH antagonist for advanced prostate cancer, acute urinary retention, and endometriosis).
Is Medicus Pharma a public or private company?
Medicus Pharma is a public company. It is classified as public and is currently operating.
When was Medicus Pharma founded?
Medicus Pharma was founded in 2008. It employs 11 to 50 people.
Where is Medicus Pharma based?
Medicus Pharma is headquartered in Toronto, Canada, in the North America region.
How does Medicus Pharma make money?
Two revenue lines are on record. Pre-revenue (clinical-stage) is the primary driver. The others are capital markets financing (non-operating).
Who are Medicus Pharma's main competitors?
Direct peers on record are Sol-Gel Technologies, Biofrontera Inc., Myovant Sciences (Sumitomo Pharma / Pfizer) and Tolmar Pharmaceuticals. Broad incumbents are Sun Pharmaceutical Industries (Levulan/Kerastick) and PellePharm (a LEO Pharma company). Emerging players are Vaxxas, Aclaris Therapeutics and Krystal Biotech. Reliant AI Inc. is listed as an others.
Does Medicus Pharma have an API?
No public API is recorded for Medicus Pharma.